Literature DB >> 34091289

The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015-2020.

Xiaoxia Liang1, Qian Yang2, Pan Wu2, Changliang He2, Lizi Yin2, Funeng Xu2, Zhongqiong Yin2, Guizhou Yue2, Yuanfeng Zou2, Lixia Li2, Xu Song2, Cheng Lv2, Wei Zhang2, Bo Jing2.   

Abstract

In the 21st century, cancer is the major public health problem worldwide. Based on the important roles of protein tyrosine kinase, the accelerated hunt for potent small-molecule tyrosine kinase inhibitors has led to the success of 30 newly inhibitors in this family for the cancer therapy in last five years. In this review, we updated their synthesis methods, and compared the original research routes with the optimized routes for each PTK inhibitor against different target, in order to make an outlook on the future synthesis of potential PTK inhibitors for anticancer therapy.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticancer drugs; Synthesis routes; Tyrosine kinase inhibitors

Year:  2021        PMID: 34091289     DOI: 10.1016/j.bioorg.2021.105011

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  8 in total

Review 1.  Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.

Authors:  Faraat Ali; Kumari Neha; Garima Chauhan
Journal:  Arch Pharm Res       Date:  2022-05-22       Impact factor: 4.946

Review 2.  Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism.

Authors:  Mohammed A S Abourehab; Alaa M Alqahtani; Bahaa G M Youssif; Ahmed M Gouda
Journal:  Molecules       Date:  2021-11-04       Impact factor: 4.411

3.  Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties.

Authors:  Aladdin M Srour; Siva S Panda; Ahmed Mostafa; Walid Fayad; May A El-Manawaty; Ahmed A F Soliman; Yassmin Moatasim; Ahmed El Taweel; Mohamed F Abdelhameed; Mohamed S Bekheit; Mohamed A Ali; Adel S Girgis
Journal:  Bioorg Chem       Date:  2021-11-04       Impact factor: 5.275

Review 4.  New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use.

Authors:  Davide Benedetto Tiz; Luana Bagnoli; Ornelio Rosati; Francesca Marini; Luca Sancineto; Claudio Santi
Journal:  Molecules       Date:  2022-03-02       Impact factor: 4.411

5.  Vinylazaarenes as dienophiles in Lewis acid-promoted Diels-Alder reactions.

Authors:  Anna E Davis; Jared M Lowe; Michael K Hilinski
Journal:  Chem Sci       Date:  2021-11-24       Impact factor: 9.825

Review 6.  Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates.

Authors:  Joseph J Barchi
Journal:  Front Immunol       Date:  2022-03-30       Impact factor: 7.561

7.  A rapid and sensitive UPLC-MS/MS method for simultaneous determination of four potential mutagenic impurities at trace levels in ripretinib drug substance.

Authors:  Yiwen Huang; Qi Xu; Hui Lu; Zhong Li; Yang Wu
Journal:  RSC Adv       Date:  2022-09-08       Impact factor: 4.036

Review 8.  Urea-based anticancer agents. Exploring 100-years of research with an eye to the future.

Authors:  Roberta Listro; Giacomo Rossino; Federica Piaggi; Falilat Folasade Sonekan; Daniela Rossi; Pasquale Linciano; Simona Collina
Journal:  Front Chem       Date:  2022-09-15       Impact factor: 5.545

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.